Company
Mountain Valley MD Holdings Inc
CNSX:MVMD
Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMD) is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies. The company applies its Quicksome desiccation technology towards the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety. It is also looking at the fight against the coronavirus (COVID-19). Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Quicksome technology has been in development since 2010, and initially incorporated into several commercial dietary supplement products. To date, the company has 14 patents in its portfolio, 12 extensions and has filed over a dozen provisional patents with respect to its Quicksome technology.
42 stories · page 1 of 3
Mountain Valley MD kicks off commercial sales of Agrarius, an agro plant technology
"Leveraging science to help eliminate harmful pesticides and chemicals often associated with agricultural practices is very aligned with our mission," said MVMD CEO Dennis Hancock
Mountain Valley MD's parasite treatment Soluvec beats ivermectin in pre-clinical pharmacokinetic study
The study tested intramuscular (IM) and subcutaneous (SC) dosing of Soluvec 1% against oral administration of ivermectin in male beagle dogs
Mountain Valley MD updates on its technologies and pre-clinical progress across broad husbandry animal and human applications
The company sees “significant potential” in treating mycobacterium-based infections in humans and animals with its solubilized format of Selactosol 1.5% and it plans to start pre-clinical studies with the drug in the “latter half of 2022”
Mountain Valley MD welcome immunologist Elizabeth Norton to an advisory position for supporting its key Quicksome vaccine
Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections
Mountain Valley MD looking to eradicate needles with its patented Quicksome oral drug delivery technology
Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience
Mountain Valley MD Holdings completes licensing agreement with Red White and Bloom Brands
CEO Dennis Hancock said the partnership with Red White & Bloom shows how Mountain Valley’s Quicksome “technology can support product innovation objectives for our key partners across a variety of market verticals”
Mountain Valley MD updates on pre-clinical progress across broad husbandry animal and human applications
The firm is developing therapies and technologies for the global pharmaceutical and nutraceutical industries
Mountain Valley MD enters into a letter of intent to complete a licensing agreement with Red White & Bloom Brands
The two companies expect to complete a product development and commercial licensing agreement before the end of October, setting out the terms under which Mountain Valley will develop one or more formulas using its Quicksome technology and
NA Proactive news snapshot: Cloud DX, Playgon Games, LQwD Fintech, Dalrada Corporation UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mountain Valley MD stock uplists to the OTCQX Best Market as it eyes US senior exchange listing
Mountain Valley MD shares will begin trading on the OTCQX Best Market under the symbol ‘MVMDF’ effective August 27, 2021
Mountain Valley MD announces appointment of Dr Azhar Rana as the company’s chief medical officer
Dr Rana brings to the company nearly two decades of life sciences experience in clinical development, pre and post-launch medical affairs, regulatory and commercial strategy, including 10 years of pharmaceutical leadership at Bristol Myers-
Mountain Valley MD Holdings appoints Gokul Kannan and Mark Gelnaw as new advisors and updates on listing plans
"I am extremely proud to welcome Gokul and Mark to our Advisory Board at Mountain Valley MD and look forward to their immediate contributions at this critical growth phase of our company," said Dennis Hancock, the CEO of Mountain Valley MD